ReviewJournal of the American Heart Association2026
From Caging to Uncaging With Bioadaptors: A Novel Paradigm in Coronary Revascularization.
Review in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The evolution of percutaneous coronary intervention has improved the outcomes of patients with coronary artery disease, but conventional drug-eluting stents remain limited by late adverse events, reduced vessel compliance, and the inability to restore physiological function. The DynamX coronary bioadaptor aims to address these issues by combining the mechanical performance of drug-eluting stents with a bioadaptive mechanism that restores natural vessel motion. The device features a cobalt-chromium scaffold connected by bioresorbable polymer elements that degrade 6 months after implantation. This process unlocks helical strands, enabling vessel pulsatility, compliance, and adaptive remodeling while maintaining lumen integrity. Preclinical studies demonstrated reduced vessel stress and restored physiological rotational motion. In the DYNAMIX (12-Month Clinical and Imaging Outcomes of the Uncaging Coronary DynamX Bioadaptor System) study, patients exhibited increased vessel area without lumen loss, optimal strut apposition, and complete neointimal coverage at 12 months. The small BIOADAPTOR-RCT (Randomized Controlled Trial of Sirolimus-Eluting Bioadaptor Versus Zotarolimus-Eluting Drug-Eluting Stent) showed noninferiority to drug-eluting stents with superior late lumen preservation and reduced neointimal hyperplasia. The larger INFINITY-SWEDEHEART (Percutaneous Coronary Intervention With a Bioadaptor Compared to a Contemporary Drug-Eluting Stent) trial confirmed low target-lesion failure rates and a plateauing of adverse events after 6 months, highlighting the benefits of vessel motion restoration. The DynamX coronary bioadaptor may represent a significant advancement in percutaneous coronary intervention by providing early mechanical support and restoring vessel function. Further studies on complex anatomy and long-term outcomes are needed to further define its role in interventional cardiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.